Roche targets Basel for its European expansion
Pharmaceutical giant Roche has announced plans for new investment at a site outside Basel as part of a European expansion drive.
The company said increased demand for biopharmaceuticals in its oncology division made the SFr480 ($435 million) investment necessary. It comes after a global review of manufacturing facilities.
Some SFr150 million will be split between syringe–filling facilities at Kaiseraugst and at a site in the German city of Mannheim.
Roche said the investment will provide stability and increased capacity in its production of popular drugs including Mircera, Pegasys and Actemra.
Chairman and CEO Franz Humer said the expansions would create hundreds of jobs in both countries.
Roche, which has its headquarters in Basel, employs about 75,000 people worldwide.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.